Acquisitions Signal Market Consolidation: P&G, Kirin, Lallemand Expand Supplement Portfolios
Major strategic acquisitions by P&G, Kirin, and Lallemand indicate a significant industry consolidation and a push towards science-backed, personalised health and enzyme solutions, impacting brand positioning and market access for SMEs.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 10 August 2026
The dietary supplement sector is undergoing significant consolidation, highlighted by three major acquisitions reported last week. Procter & Gamble (P&G) has agreed to acquire Thorne for US$3.8 billion, a move set to bolster its presence in science-backed wellness and personalised health. Thorne, which generates over US$500 million in annual revenue, has strategically shifted its focus to younger consumers, positioning itself for growth in the performance-oriented health segment. This acquisition, pending regulatory approvals, is expected to close later this year, giving P&G a strong foothold in a rapidly evolving market segment, according to Thorne CEO Colin Watts.
Concurrently, Japan's Kirin Holdings Company is expanding its Health Science division into North America with the C$2.5 billion (US$1.78 billion) acquisition of Jamieson Wellness Inc. This follows Kirin's earlier acquisitions of Blackmores (2023) and FANCL (2024), establishing a strong foundation across Asia and Oceania. Kirin views Jamieson Wellness as a strategic fit due to its established brands, extensive distribution networks, and end-to-end capabilities spanning R&D, manufacturing, and sales. Alastair Symington, CEO & Managing Director of Blackmores Limited, stated this acquisition creates a unified global platform across North America, Asia, and Oceania, combining Kirin's fermentation and biotechnology expertise with Jamieson's market strengths.
In the ingredient space, Canada's Lallemand Inc. has completed the acquisition of Virginia-based BIO-CAT Enzymes & Microbials. While terms were not disclosed, this acquisition, effective 31 July 2026, significantly enhances Lallemand's US production capacity and footprint, adding two facilities in Virginia and Minnesota to its existing 45+ global sites. BIO-CAT, founded in 1988, is known for its enzyme and microbial solutions. Antoine Chagnon, CEO of Lallemand, indicated the acquisition would reinforce Lallemand's presence in dietary food supplement and health ingredient markets, improving capability to meet customer requirements across various industries.
What this means for United Kingdom
UK brand owners face intensified competition from multinational entrants with deeper pockets and integrated supply chains. P&G's move into personalised nutrition via Thorne signals a premiumisation trend, requiring local brands to differentiate through novel ingredients or niche positioning to retain market share. Kirin's North American expansion, combined with its Asian presence, indicates a global play that could eventually target European markets, potentially increasing acquisition targets for UK-based innovation. Ingredient procurement leads should note Lallemand's increased enzyme and microbial capacity, which may stabilise supply and potentially competitive pricing, though MOQs could remain a barrier for smaller formulators. Compliance teams must prepare for potential harmonisation pressures if these large players advocate for global regulatory standards.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.